title: Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.
abstract: OBJECTIVE
  To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.
  
  
  METHODS
  A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.
  
  
  RESULTS
  Patients presented at a mean age of 69 years (range 44-86). Mean duration of symptoms was 40 weeks (range 1-300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) microm, declining to 316 (41) microm at 6 months.
  
  
  CONCLUSIONS
  Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.
authors.affiliation: Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Mathildenstr 8, 80336 Munich, Germany.
authors.forename: T C
authors.initials: TC
authors.lastname: Kreutzer
authors.forename: C S
authors.initials: CS
authors.lastname: Alge
authors.forename: A H
authors.initials: AH
authors.lastname: Wolf
authors.forename: D
authors.initials: D
authors.lastname: Kook
authors.forename: J
authors.initials: J
authors.lastname: Burger
authors.forename: R
authors.initials: R
authors.lastname: Strauss
authors.forename: C
authors.initials: C
authors.lastname: Kunze
authors.forename: C
authors.initials: C
authors.lastname: Haritoglou
authors.forename: A
authors.initials: A
authors.lastname: Kampik
authors.forename: S
authors.initials: S
authors.lastname: Priglinger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004334:Drug Administration Schedule; D005260:Female; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab